<DOC>
	<DOCNO>NCT01334996</DOCNO>
	<brief_summary>In study , investigator determine utility Tamoxifen , non-cytotoxic agent , improve quality life , biochemical parameter , bone marrow involvement systemic mastocytosis patient 1 ) 20 % bone marrow infiltration mast cell and/or 2 ) mediator-release symptom control tolerated dos standard `` non-cytotoxic '' medication regardless percentage bone marrow involvement mastocytosis . The dose Tamoxifen 20 mg/day duration treatment one year . Patients currently take interferon alfa , imatinib mesylate , cladribine exclude medication stop .</brief_summary>
	<brief_title>Use Tamoxifen Systemic Mastocytosis</brief_title>
	<detailed_description>Not desire</detailed_description>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Systemic Mastocytosis Current treatment Imatinib mesylate , cladribine interferon alpha .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>